Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
暂无分享,去创建一个
H. Uno | M. Pfeffer | J. McMurray | G. Remuzzi | H. Skali | A. Nissenson | Ajay K. Singh | R. Toto | P. Parfrey | M. Cooper | J. Rossert | N. Scott-Douglas | Peter Ivanovich | Julie Lin | Chao-Yin Chen
[1] M. Tonelli,et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. , 2014, The Cochrane database of systematic reviews.
[2] H. Uno,et al. Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa: The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience , 2011, Circulation.
[3] H. Uno,et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. , 2010, The New England journal of medicine.
[4] R. Alcázar,et al. Cambiará la prescripción de agentes estimulantes de la eritropoyesis en prediálisis tras los resultados del estudio TREAT , 2010 .
[5] S. Solomon,et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.
[6] H. Uno,et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] K. Kalantar-Zadeh,et al. Hemoglobin variability in anemia of chronic kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.
[8] N. Milman,et al. Blood haemoglobin concentrations are higher in smokers and heavy alcohol consumers than in non-smokers and abstainers—should we adjust the reference range? , 2009, Annals of Hematology.
[9] M. Pfeffer. Critical missing data on erythropoiesis-stimulating agents in CKD: first beat placebo. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] H. Burger,et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.
[11] Huiman Barnhart,et al. Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.
[12] R. Foley,et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. , 2005, Journal of the American Society of Nephrology : JASN.
[13] S. Solomon,et al. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. , 2005, American heart journal.
[14] S. Yusuf,et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. , 2005, Journal of the American College of Cardiology.
[15] W. Winkelmayer,et al. Pharmacoepidemiology of anemia in kidney transplant recipients. , 2004, Journal of the American Society of Nephrology : JASN.
[16] A. Collins,et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. , 2001, Journal of the American Society of Nephrology : JASN.
[17] A R Nissenson,et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.
[18] D. Nordenberg,et al. The effect of cigarette smoking on hemoglobin levels and anemia screening. , 1990, JAMA.
[19] J. Adamson,et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. , 1989, Annals of internal medicine.